IL154977A0 - Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent - Google Patents

Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent

Info

Publication number
IL154977A0
IL154977A0 IL15497701A IL15497701A IL154977A0 IL 154977 A0 IL154977 A0 IL 154977A0 IL 15497701 A IL15497701 A IL 15497701A IL 15497701 A IL15497701 A IL 15497701A IL 154977 A0 IL154977 A0 IL 154977A0
Authority
IL
Israel
Prior art keywords
immunosuppressor
immunomodulator
statins
hmg
coa reductase
Prior art date
Application number
IL15497701A
Other languages
English (en)
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of IL154977A0 publication Critical patent/IL154977A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
IL15497701A 2000-09-19 2001-09-19 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent IL154977A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66487100A 2000-09-19 2000-09-19
PCT/EP2001/011485 WO2002024194A2 (fr) 2000-09-19 2001-09-19 Statines (inhibiteurs de la hmg-coa reductase) en tant que nouveau type d'agent immunomodulateur, immunosuppresseur et anti-inflammatoire

Publications (1)

Publication Number Publication Date
IL154977A0 true IL154977A0 (en) 2003-10-31

Family

ID=24667787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15497701A IL154977A0 (en) 2000-09-19 2001-09-19 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent

Country Status (7)

Country Link
US (4) US20020156122A1 (fr)
EP (1) EP1322306A2 (fr)
JP (1) JP2004512278A (fr)
AU (1) AU2002210521A1 (fr)
CA (1) CA2422820A1 (fr)
IL (1) IL154977A0 (fr)
WO (1) WO2002024194A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
WO1999026657A1 (fr) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
ES2192988B1 (es) * 2002-02-28 2005-02-16 Jose Manuel Quesada Gomez Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
WO2003082269A1 (fr) * 2002-03-29 2003-10-09 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de statines et d'autres agents immunomodulateurs dans le traitement des maladies auto-immunes
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
SG157242A1 (en) * 2004-02-14 2009-12-29 Smithkline Beecham Corp Medicaments with hm74a receptor agonist activity
CA2560167A1 (fr) * 2004-04-26 2005-11-10 Alcon, Inc. Statines pour le traitement de l'hypertension oculaire et du glaucome
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
WO2006086500A2 (fr) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions et methodes pour traiter des maladies vasculaires, auto-immunes et inflammatoires
US20090227602A1 (en) * 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CN102772411A (zh) * 2006-07-05 2012-11-14 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US20090312411A1 (en) * 2008-03-27 2009-12-17 New York Society For The Raptured And Crippled Maintaining The Hospital For Special Surgery Preventing or reducing risk of miscarriages
JP2014133703A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
JP5678566B2 (ja) * 2010-10-15 2015-03-04 国立大学法人大阪大学 乾癬予防治療剤
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012170417A2 (fr) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Procédés et compositions pour améliorer la croissance osseuse comprenant une statine
US11458154B2 (en) 2013-09-06 2022-10-04 Vanda Pharmaceuticals Inc. Treatment of CYR61- and VEGF-mediated conditions
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632988A (en) * 1989-10-23 1997-05-27 Schering Corporation Polypeptide inhibitors of gamma interferon
CA2109120A1 (fr) * 1991-05-01 1992-11-12 Terence J. Scallen Induction de differentiation cellulaire a l'aide de derives de mevalonate et de mevalonolactone
AU2556195A (en) * 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
CA2205680A1 (fr) * 1997-05-16 1998-11-16 The University Of Western Ontario Peptide clip immunomodulateur
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
WO1999026657A1 (fr) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
CA2327504A1 (fr) * 1998-04-29 1999-11-04 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines a interaction cd40 et a interaction traf
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
WO2000053566A1 (fr) * 1999-03-08 2000-09-14 Merck & Co., Inc. Sel de calcium hydrate et cristallin de simvastatine d'acide ouvert en dihydroxy
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof

Also Published As

Publication number Publication date
US20050187285A1 (en) 2005-08-25
CA2422820A1 (fr) 2002-03-28
US20020159973A1 (en) 2002-10-31
JP2004512278A (ja) 2004-04-22
WO2002024194A3 (fr) 2003-03-13
WO2002024194A2 (fr) 2002-03-28
AU2002210521A1 (en) 2002-04-02
EP1322306A2 (fr) 2003-07-02
WO2002024194A9 (fr) 2002-09-19
US20020156122A1 (en) 2002-10-24
US20040102512A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
HK1200368A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor hmg coa
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
PL359820A1 (en) Hmg-coa reductase inhibitors and method
IL169090A0 (en) Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
IL166279A0 (en) Composition comprising a cholesterol absorption inhibitor an HMG-COA reductase inhibitor and a stabilizing agent
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
EP1286702A4 (fr) Inhibiteurs de la hmg coa reductase pour favoriser l'angiogenese
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2003270154A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
AU2116201A (en) A therapeutic mixture of hmg-coa reductase inhibitors
HUP0201597A3 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
HUP0105145A3 (en) Process for producing hmg-coa reductase inhibitor
EP1404313A4 (fr) ANALOGUES METHYLE DE SIMVASTATINE UTILISES COMME NOUVEAUX INHIBITEURS DE REDUCTASE HMG-CoA
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
AU2001228647A1 (en) Dihydrofolate reductase inhibitors
AU2001289428A1 (en) Oral pharmaceutical composition containing a combination of fenofibrate and a hmg-coa reductase inhibitor
AU2002331468A1 (en) Oral pharmaceutical composition containing a combinaition of pparalpha and a hmg-coa reductase inhibitor
SI1114021T1 (en) NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS